Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings

@article{Shoemaker2013VasoactiveIP,
  title={Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings},
  author={Ritchie C. Shoemaker and Dennis E. House and James C. Ryan},
  journal={Health},
  year={2013},
  volume={05},
  pages={396-401}
}
Exposure in water-damaged buildings (WDB) to airborne bioaerosols including metabolic products of toxigenic fungi, bacteria and actinomycetes; and inflammagens, can lead to a persistent innate immune inflammatory illness. [] Key Method Here we report an open label trial of 20 patients with refractory CIRS-WDB illness who took replacement VIP in a nasal spray for at least 18 months with confirmation of durable efficacy and absence of significant side effects.
View PDF
16 Citations
Background Citations
4
Methods Citations
2

Figures and Tables from this paper

16 Citations

RNA-Seq on patients with chronic inflammatory response syndrome (CIRS) treated with vasoactive intestinal peptide (VIP) shows a shift in metabolic state and innate immune functions that coincide with healing

Several key immune regulators were found to be differentially expressed over the course of treatment with VIP, including CD244, CD3D, CD48 and CD52, granzymes, defensins, and the Ikaros family of lymphoid transcription factors, indicating a calming of components of immune responses.

Chronic Inflammatory Response Syndrome Acquired After Exposure to Water- Damaged Buildings (CIRS-WDB)

The illness acquired after exposure to WDB is referred to as "Chronic Inflammatory Response Syndrome acquired following exposure to the interior environment of Water-Damaged Buildings", or CIRS-WDB.

Internal medicine review Urinary Mycotoxins: A Review of Contaminated Buildings and Food in Search of a Biomarker Separating Sick Patients from Controls October 2019

There have been an increasing number of patients with a chronic multisystem illness who have been using measurements of mycotoxins in urine to diagnose a putative illness for which antifungals in various forms (oral, IV, sublingual and intranasal) are being used as therapy.

Treatable metabolic and inflammatory abnormalities in Post COVID Syndrome (PCS) define the transcriptomic basis for persistent symptoms: Lessons from CIRS

The data reported here supports the concept that Post-COVID Syndrome occurs in patients with additional environmental exposures and enhanced TGF signaling, and a new approach to the treatment of PCS is suggested.

Intranasal VIP safely restores volume to multiple grey matter nuclei in patients with CIRS

A course of VIP treatment that restores grey matter nuclear atrophy in CIRS patients is identified and safety and durability of benefit were both shown with no significant adverse effects reported by any patients.

Evaluation of the Ratio of T Helper 17 and T Regulatory Cells in Patients with Chronic Idiopathic Urticaria

The high expression of FOXP3 in patients without any significant changes in RORγt might indicate the presence of an independent inflammatory pathway such as neurogenic inflammation, which induces Treg cells and mediates inflammation through the degranulation of mast cells.

Neurogenic Inflammation Involves in Systemic Spread of Oral Infection

Neurogenic inflammation involved in systemic spread of oral infection was able to downregulate inflammation in distant organ posibly by stimulating VIP as verified by analysing CGRP, VIP and TNF-α expressions.

Reversal of Refractory Ulcerative Colitis and Severe Chronic Fatigue Syndrome Symptoms Arising from Immune Disturbance in an HLADR/DQ Genetically Susceptible Individual with Multiple Biotoxin Exposures

Re reversal of co-existing RUC and CFS symptoms arising from biotoxin exposures in a genetically susceptible individual is reported and may represent a treatable underlying disease etiology in a subset of genetically susceptible patients with RUC, CFS, and other immune disorders.

Metabolism, molecular hypometabolism and inflammation: Complications of proliferative physiology include metabolic acidosis, pulmonary hypertension, T reg cell deficiency, insulin resistance and neuronal injury

Open-label treatment of CIRS patients with MHM, following a published protocol, showed clinical improvement over stereotyped baseline proteomic abnormalities and reversal of gene suppression, seen as an overshoot of mRNA number in cases compared to controls and correction by VIP of the overshoot to equal controls.

Reduction in Forebrain Parenchymal and Cortical Grey Matter Swelling across Treatment Groups in Patients with Inflammatory Illness Acquired Following Exposure to Water-Damaged Buildings

Previous findings of increased forebrain parenchymal, cortical gray matter and pallidum volumes, as well as decreased caudate nucleus volumes in untreated CIRS patients compared to controls are reinforced.

References

SHOWING 1-10 OF 18 REFERENCES

Defining the neurotoxin derived illness chronic ciguatera using markers of chronic systemic inflammatory disturbances: a case/control study.

Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis.

This study is the first to show the immunoregulatory effect of VIP in humans, and supports the notion of inhaled VIP as an attractive future therapy to dampen exaggerated immune responses in lung disorders.

Role of vasoactive intestinal peptide in inflammation and autoimmunity.

The central functions that VIP plays in cellular processes is being recognized and attention is being focused on this important peptide with regard to exciting new candidates for therapeutic intervention and drug development.

Vasoactive Intestinal Peptide Regulates Th17 Function in Autoimmune Inflammation

Arising new data and a critical revision of already published studies indicate that VIP is an immunomodulatory therapeutic agent targeting the Th17/Treg pathway.

Anti‐inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock

The higher effectiveness of theVPAC1 agonist compared with the VPAC2 agonist suggests that VPAC1 is the major mediator of the anti‐inflammatory action of VIP, which might provide a more efficient therapeutical alternative to the use of specific cytokine antibodies or antagonists.

Research Committee Report on Diagnosis and Treatment of Chronic Inflammatory Response Syndrome Caused by Exposure to the Interior Environment of Water-Damaged Buildings

The literature the authors cite throughout this document supports the concept that exposure to the interior environment of WDB creates abnormal inflammatory responses that are both biomarkers for the presence of the illness and guides for therapy.

Innate immunity , MR spectroscopy , HLA DR , TGF beta-1 , VIP and capillary hypoperfusion define acute and chronic human illness acquired following exposure to water-damaged buildings

Profiling cases compared to controls based on innate immunity abnormalities that are correlated with measures of capillary hypoperfusion resulted in accurate classification of WDB-illness.

Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease

Administration of the neuropeptide vasoactive intestinal peptide significantly reduced incidence and severity of arthritis in an experimental model, completely abrogating joint swelling and destruction of cartilage and bone.

Vasoactive intestinal peptide induces vascular endothelial growth factor production in human HaCaT keratinocytes via MAPK pathway

Regulation of Dendritic Cell Differentiation by Vasoactive Intestinal Peptide

The effect of VIP on the DC‐Treg axis represents an additional mechanism for their general anti‐inflammatory role, particularly relevant in autoimmunity and transplantation.